Aptinyx Inc. (APTX)

Market Cap	4.67M
Revenue (ttm)	n/a
Net Income (ttm)	-29.17M
Shares Out	67.72M
EPS (ttm)	-0.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,414
Open	0.0715
Previous Close	0.0715
Day's Range	0.0681 - 0.0757
52-Week Range	0.0500 - 0.7200
Beta	1.37
Analysts	Hold
Price Target	0.50 (+624.64%)
Earnings Date	Aug 29, 2023

About APTX

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. wa...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 12
• Stock Exchange: OTCMKTS
• Ticker Symbol: APTX

Analyst Forecast

According to 2 analysts, the average rating for APTX stock is "Hold." The 12-month stock price forecast is $0.5, which is an increase of 624.64% from the latest price.

Price Target

$0.5

(624.64% upside)

Analyst Consensus: Hold